Results from two phase III trials (NRG-GY018 and RUBY01) presented earlier this year at the Society of Gynecologic Oncology (SGO) annual meeting demonstrated that immunotherapy combined with standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback